Ping An Biomedical Co., Ltd. (PASW) 股票分析

公司概述

Ping An Biomedical Co., Ltd. operates primarily through its subsidiaries to deliver comprehensive supply chain management services within the apparel industry, with a geographic footprint spanning China, Hong Kong, Cambodia, and Europe. The company's core operational activities encompass market trend analysis, product design and development, raw material sourcing, production management, quality control, and logistics. This entity functions within the Consumer Cyclical sector, specifically classified under the Textile Manufacturing industry, positioning it as a player in the broader manufacturing landscape that is sensitive to consumer spending patterns. As of the latest reporting period, the company holds a market capitalization of $18.31 million, generates annual revenue of $34.15 million, and employs a workforce of 7 individuals. These valuation and revenue figures suggest a company with a relatively small market presence and limited operational scale, indicative of a micro-cap entity where a single employee count and modest revenue stream define its current standing in the competitive textile market.

财务健康

The company reported revenue of $34.15 million over the trailing twelve months, yet it posted a net income of -$12,829,206 and an EBITDA of -$14,695,886, revealing a severe structural disconnect between top-line sales and bottom-line profitability. The substantial gap between the positive revenue figure and the deeply negative net income highlights an extremely fragile cost structure where operating expenses vastly outweigh gross profits, resulting in a gross margin of only 2.8%. This thin gross margin leaves insufficient cushion to cover overheads, leading to an operating margin of -69.6% and a profit margin of -37.6%, which collectively indicate that the company is losing money on a significant portion of its sales volume. The firm generated free cash flow of -$59,241,688, a metric that demonstrates a critical lack of financial flexibility and an inability to fund operations or capital expenditures from internal cash generation. On the balance sheet, the company holds cash of $1.17 million against total debt of $10.47 million, resulting in a debt-to-equity ratio of 23.14, which characterizes the capital structure as highly leveraged and potentially vulnerable to liquidity stress. Despite the high debt load, the current ratio stands at 2.76, suggesting that the company technically maintains sufficient current assets to cover its short-term liabilities, though the quality of those assets remains questionable given the cash shortfall. Furthermore, the return on equity is -67.4% and the return on assets is -14.7%, metrics that reveal management has been ineffective in generating value from shareholders' capital or the company's total asset base over the reporting period.

估值评估

The P/E Ratio (TTM) and Forward P/E are both listed as N/A, reflecting the fact that the company is currently unprofitable, which renders traditional earnings-based valuation multiples inapplicable for assessing future earnings trajectory or growth expectations. In the absence of a positive earnings multiple, the price-to-book ratio of 0.46 serves as a primary valuation indicator, suggesting that the market values the company at less than half of its book value, which often occurs in distressed or turnaround situations. The price-to-sales ratio is recorded at 0.54, and the EV/EBITDA stands at -0.88, providing alternative perspectives that the company's enterprise value is negative relative to its earnings power due to the cumulative losses. Regarding price volatility, the 52-week high is $5.40 and the 52-week low is $0.12, indicating a massive price swing typical of speculative small-cap stocks, though the exact current trading price relative to this range cannot be calculated without the specific share price input. The beta is listed as N/A, meaning there is no available historical data to quantify the stock's price volatility relative to the broader market index. These valuation metrics collectively paint a picture of an asset trading at a deep discount to its book value with no earnings support, reflecting high perceived risk in the valuation model.

Growth & Income

The revenue growth year-over-year is -62.0%, while the earnings growth is N/A due to the absence of profitable earnings in the prior period, implying that the company is currently in a contraction phase rather than a growth phase. Since the company reports a net loss, the concept of earnings growing faster or slower than revenue is moot, but the negative revenue growth confirms a shrinking top line that exacerbates the company's financial distress. The dividend yield is N/A and the payout ratio is 0.0%, indicating that the company does not distribute any dividends to shareholders. This non-dividend status means the company retains its minimal cash reserves, if any, for operational survival rather than rewarding shareholders with income. Consequently, the overall growth and income profile is characterized by significant revenue contraction, negative profitability, and a total lack of dividend income, presenting a challenging investment scenario focused solely on potential operational turnaround rather than income generation or stable growth.